A study published in Cochrane Library assessed the effects of interleukin-2 as an adjunct to antiretroviral therapy for HIV-positive adults.
HIV continues to be a leading cause of morbidity and mortality, particularly in sub-Saharan Africa. Although antiretroviral drugs have helped to improve the quality of life and life expectancy of HIV-positive individuals, there is still a need to explore other interventions that will help to further reduce the disease burden. One potential strategy is the use of interleukin-2 (IL-2) in combination with antiretroviral therapy. IL-2 is a cytokine that regulates the proliferation and differentiation of lymphocytes and may help to boost the immune system.
To read the full publication, click here.